Letter: Detection of infliximab levels and anti-infliximab antibodies - Comparison of three different assays; Authors' reply

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 2, 2013, Pages 282-

  Buurman, D J ^a   Vande Casteele, N ^b   Sturkenboom, M G G ^a   Kleibeuker, J H ^a   Vermeire, S ^b   Van Der Kleij, D ^c   Rispens, T ^d   Gils, A ^b   Dijkstra, G ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Sanquin Diagnostics   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB;

ASSAY; FALSE POSITIVE RESULT; LETTER; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOASSAY;

EID: 84872841937     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12128     Document Type: Letter

References (3)

1. Parussini E,. Letter: detection of infliximab levels and anti-infliximab antibodies-comparison of three different assays. Aliment Pharmacol Ther 2013; 37: 281.
2. Vande Casteele N, Buurman DJ, Sturkenboom MG, et al,. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012; 36: 765-71.
3. Pariente B, de Chambrun GP, Krzysiek R, et al,. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 18: 1199-206.